Curevac (CVAC)

$3.72

+0.08

(+2.2%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $3.60
    $3.74
    $3.72
    downward going graph

    3.23%

    Downside

    Day's Volatility :3.74%

    Upside

    0.53%

    downward going graph
  • $2.22
    $10.14
    $3.72
    downward going graph

    40.32%

    Downside

    52 Weeks Volatility :78.11%

    Upside

    63.31%

    downward going graph

Returns

PeriodCurevacSector (Health Care)Index (Russel 2000)
3 Months
56.22%
6.5%
0.0%
6 Months
1.96%
7.1%
0.0%
1 Year
-57.23%
9.8%
0.0%
3 Years
-93.28%
14.2%
-20.2%

Highlights

Market Capitalization
807.5M
Book Value
$1.99
Earnings Per Share (EPS)
-1.33
Wall Street Target Price
8.33
Profit Margin
0.0%
Operating Margin TTM
-623.03%
Return On Assets TTM
-21.53%
Return On Equity TTM
-47.11%
Revenue TTM
59.0M
Revenue Per Share TTM
0.26
Quarterly Revenue Growth YOY
73.6%
Gross Profit TTM
-91.5M
EBITDA
-270.8M
Diluted Eps TTM
-1.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.01
EPS Estimate Next Year
-0.61
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Buy
    66%Buy
    26%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Curevac(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
11
11
Hold
4
3
3
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 123.92%

Current $3.72
Target $8.33

Company Financials

FY18Y/Y Change
Revenue
14.7M
-
Net Income
-81.5M
-
Net Profit Margin
-553.5%
-
FY19Y/Y Change
Revenue
19.5M
↑ 35.31%
Net Income
-111.9M
↑ 40.19%
Net Profit Margin
-573.46%
↓ 19.96%
FY20Y/Y Change
Revenue
60.1M
↑ 180.78%
Net Income
-158.8M
↑ 29.24%
Net Profit Margin
-263.96%
↑ 309.5%
FY21Y/Y Change
Revenue
116.6M
↑ 110.61%
Net Income
-466.3M
↑ 218.98%
Net Profit Margin
-399.76%
↓ 135.8%
FY22Y/Y Change
Revenue
72.2M
↓ 34.54%
Net Income
-266.8M
↓ 39.51%
Net Profit Margin
-369.37%
↑ 30.39%
FY23Y/Y Change
Revenue
52.7M
↓ 21.9%
Net Income
-254.8M
↑ 2.33%
Net Profit Margin
-483.96%
↓ 114.59%
Q4 FY22Q/Q Change
Revenue
12.5M
↑ 4.25%
Net Income
-138.0M
↑ 170.74%
Net Profit Margin
-1.1K%
↓ 677.49%
Q1 FY23Q/Q Change
Revenue
12.7M
↑ 0.0%
Net Income
-140.4M
↑ 0.0%
Net Profit Margin
-1.1K%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
8.3M
↓ 35.16%
Net Income
-73.6M
↓ 47.65%
Net Profit Margin
-889.48%
↑ 212.27%
Q3 FY23Q/Q Change
Revenue
16.5M
↑ 117.48%
Net Income
-48.7M
↓ 27.79%
Net Profit Margin
-295.34%
↑ 594.14%
Q4 FY23Q/Q Change
Revenue
22.6M
↑ 36.91%
Net Income
-86.7M
↑ 78.0%
Net Profit Margin
-383.98%
↓ 88.64%
Q1 FY24Q/Q Change
Revenue
23.7M
↓ 2.57%
Net Income
-91.2M
↓ 2.57%
Net Profit Margin
-383.98%
↑ 0.0%
FY18Y/Y Change
Total Assets
143.8M
-
Total Liabilities
107.1M
-
FY19Y/Y Change
Total Assets
146.3M
↑ 3.95%
Total Liabilities
194.3M
↑ 85.33%
FY20Y/Y Change
Total Assets
1.9B
↑ 1057.06%
Total Liabilities
984.0M
↑ 361.31%
FY21Y/Y Change
Total Assets
1.3B
↓ 23.36%
Total Liabilities
532.0M
↓ 41.28%
FY22Y/Y Change
Total Assets
921.8M
↓ 25.71%
Total Liabilities
350.5M
↓ 30.34%
FY23Y/Y Change
Total Assets
788.9M
↓ 8.32%
Total Liabilities
271.5M
↓ 17.02%
Q4 FY22Q/Q Change
Total Assets
921.8M
↓ 5.5%
Total Liabilities
350.5M
↑ 14.6%
Q1 FY23Q/Q Change
Total Assets
938.4M
↑ 0.0%
Total Liabilities
356.8M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
981.4M
↑ 4.53%
Total Liabilities
273.2M
↓ 23.47%
Q3 FY23Q/Q Change
Total Assets
842.6M
↓ 6.33%
Total Liabilities
240.3M
↓ 4.05%
Q4 FY23Q/Q Change
Total Assets
788.2M
↓ 6.45%
Total Liabilities
271.3M
↑ 12.9%
Q1 FY24Q/Q Change
Total Assets
851.8M
↑ 0.08%
Total Liabilities
293.2M
↑ 0.08%
FY18Y/Y Change
Operating Cash Flow
-84.8M
-
Investing Cash Flow
-4.9M
-
Financing Cash Flow
-128.1K
-
FY19Y/Y Change
Operating Cash Flow
-97.4M
↑ 17.34%
Investing Cash Flow
31.6M
↓ 760.91%
Financing Cash Flow
76.1M
↓ 60795.54%
FY20Y/Y Change
Operating Cash Flow
642.6M
↓ 700.72%
Investing Cash Flow
-55.7M
↓ 260.65%
Financing Cash Flow
1.0B
↑ 1106.01%
FY21Y/Y Change
Operating Cash Flow
-830.3M
↓ 240.34%
Investing Cash Flow
-144.8M
↑ 182.5%
Financing Cash Flow
390.7M
↓ 57.92%
Q4 FY22Q/Q Change
Operating Cash Flow
-52.6M
↑ 36.67%
Investing Cash Flow
-14.4M
↓ 51.8%
Financing Cash Flow
35.7M
↑ 25.83%
Q1 FY23Q/Q Change
Operating Cash Flow
-53.5M
↑ 0.0%
Investing Cash Flow
-14.6M
↑ 0.0%
Financing Cash Flow
36.3M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-70.0M
↑ 30.62%
Investing Cash Flow
-14.6M
↑ 0.0%
Financing Cash Flow
-1.3M
↓ 103.59%
Q3 FY23Q/Q Change
Operating Cash Flow
-60.6M
↓ 5.52%
Investing Cash Flow
-13.4M
↑ 0.0%
Financing Cash Flow
-1.2M
↑ 1.25%

Technicals Summary

Sell

Neutral

Buy

Curevac is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Curevac
Curevac
8.17%
1.96%
-57.23%
-93.28%
-93.49%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Curevac
Curevac
NA
NA
NA
-0.01
-0.47
-0.22
NA
1.99
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Curevac
Curevac
Buy
$807.5M
-93.49%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Curevac

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 22.56M → 21.98M (in $), with an average decrease of 2.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -86.65M → -84.42M (in $), with an average increase of 2.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 118.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 279.8%

Institutional Holdings

  • Millennium Management LLC

    1.23%

  • BlackRock Inc

    0.88%

  • RA Capital Management, LLC

    0.88%

  • Camber Capital Management LLC

    0.78%

  • Bill & Melinda Gates Foundation

    0.71%

  • Morgan Stanley - Brokerage Accounts

    0.38%

Company Information

founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o

Organization
Curevac
Employees
999
CEO
Mr. Pierre Kemula B.Sc.
Industry
Health Technology

Discover More

FAQs